{"entity":{"id":"nct06733038","kind":"trial","name":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","aka":["AtezoTRIBE2"],"tldr":"A phase 3 trial of atezolizumab, bevacizumab (glioblastoma use), fOLFIRI (5-FU, leucovorin, irinotecan), fOLFOX (5-FU, leucovorin, oxaliplatin) and other drugs in colorectal cancer, run by Gruppo Oncologico del Nord-Ovest, now recruiting.","summary":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. is a phase 3, randomised interventional study registered as NCT06733038 by Gruppo Oncologico del Nord-Ovest, with a registry enrolment figure of 238 participants, started 2024-11-15 and due to reach its primary completion in 2028-04-01. Interventions recorded: Atezolizumab; Bevacizumab; Irinotecan (CPT-11); Oxaliplatin; Leucovorin; Fluorouracil (5-FU). Conditions listed: Colorectal Cancer. Primary outcome: Progression Free Survival (PFS). Colorectal eligibility wording from the registry: \"* Histologically proven diagnosis of colorectal cancer;\". Sites: Italy. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06733038","url":"https://clinicaltrials.gov/study/NCT06733038"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["atezolizumab","bevacizumab-glioma","folfiri","folfox","fluorouracil"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06733038","phase":"3","setting":"Phase III Randomized Study of FOLFOXIRI Plus Bevacizumab and Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-Line Treatment of Unresectable pMMR and Immunoscore IC-High Metastatic Colorectal Cancer Patients","sponsor":"Gruppo Oncologico del Nord-Ovest","enrolled":238,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06733038/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}